Crinetics Pharmaceuticals, Inc.
CRNX
Rang în acțiuni
#2225
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Preț acțiune
$84.95
Ultima sincronizare: 2026-09-01
Capitalizare de piață
$9.00B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
98.25%
Țară
US
Tranzacționează Crinetics Pharmaceuticals, Inc. (CRNX)
Categorie
Healthcare
Venituri pentru Crinetics Pharmaceuticals, Inc. (CRNX)
Venituri în Jun 2026 TTM: $42.16M
Conform celor mai recente rapoarte financiare ale Crinetics Pharmaceuticals, Inc., venitul actual al companiei (TTM) este $42.16M. În anul 2023, compania a avut un venit de $4.01M o scădere comparativ cu venitul din anul 2022, care a fost de $4.74M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Crinetics Pharmaceuticals, Inc. din 2016 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $42.16M | 3,957.36% |
| 2024 | $1.04M | -74.11% |
| 2023 | $4.01M | -15.28% |
| 2022 | $4.74M | 339.42% |
| 2021 | $1.08M | 1,418.31% |
| 2020 | $71.00K | -94.05% |
| 2019 | $1.19M | -50.86% |
| 2018 | $2.43M | 18.73% |
| 2017 | $2.05M | 247.20% |
| 2016 | $589.00K | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 29,846.63% |
US
|
|
| $2.23B | 5,185.13% |
US
|
|
| $15.74B | 37,247.77% |
AU
|
|
| $6.02B | 14,183.35% |
NL
|
|
| - | - |
CH
|
